From the guest editor: the evolving treatment paradigm in multiple myeloma.

Suppr

超能文献

作者信息

Anderson Kenneth C

出版信息

Cancer J. 2009 Nov-Dec;15(6):456. doi: 10.1097/PPO.0b013e3181c64fae.

DOI:10.1097/PPO.0b013e3181c64fae

PMID:20010163

Abstract

摘要

相似文献

From the guest editor: the evolving treatment paradigm in multiple myeloma.

Cancer J. 2009 Nov-Dec;15(6):456. doi: 10.1097/PPO.0b013e3181c64fae.

[Therapeutic outcomes in systemic lymphatic diseases and plasmacytoma. New hope for palliative patients].

MMW Fortschr Med. 2005 Jun 16;147(24):23.

Multiple myeloma.

N Engl J Med. 2004 Oct 28;351(18):1860-73. doi: 10.1056/NEJMra041875.

Risk stratification in the era of novel therapies.

Cancer J. 2009 Nov-Dec;15(6):457-64. doi: 10.1097/PPO.0b013e3181c51efa.

Evolving role of novel agents for maintenance therapy in myeloma.

Cancer J. 2009 Nov-Dec;15(6):494-501. doi: 10.1097/PPO.0b013e3181c51f24.

Multiple myeloma therapies.

Nat Rev Drug Discov. 2007 Mar;6(3):181-2. doi: 10.1038/nrd2269.

Testicular invading refractory multiple myeloma during bortezomib treatment successfully treated with lenalidomide: a case report.

Ann Hematol. 2014 Mar;93(3):529-30. doi: 10.1007/s00277-013-1835-9. Epub 2013 Jul 3.

Clinical assessment of bortezomib for multiple myeloma in comparison with thalidomide.

J Pharm Pharm Sci. 2011;14(1):78-89.

Clinical management of myeloma--state of the art.

Cancer Treat Rev. 2010 May;36 Suppl 2:S1-2. doi: 10.1016/S0305-7372(10)00081-2.

New agents and approaches in the treatment of multiple myeloma.

Clin Adv Hematol Oncol. 2003 Mar;1(3):151-2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

From the guest editor: the evolving treatment paradigm in multiple myeloma.

Cancer J. 2009 Nov-Dec;15(6):456. doi: 10.1097/PPO.0b013e3181c64fae.

[Therapeutic outcomes in systemic lymphatic diseases and plasmacytoma. New hope for palliative patients].

MMW Fortschr Med. 2005 Jun 16;147(24):23.

Multiple myeloma.

N Engl J Med. 2004 Oct 28;351(18):1860-73. doi: 10.1056/NEJMra041875.

Risk stratification in the era of novel therapies.

Cancer J. 2009 Nov-Dec;15(6):457-64. doi: 10.1097/PPO.0b013e3181c51efa.

Evolving role of novel agents for maintenance therapy in myeloma.

Cancer J. 2009 Nov-Dec;15(6):494-501. doi: 10.1097/PPO.0b013e3181c51f24.

Multiple myeloma therapies.

Nat Rev Drug Discov. 2007 Mar;6(3):181-2. doi: 10.1038/nrd2269.

Testicular invading refractory multiple myeloma during bortezomib treatment successfully treated with lenalidomide: a case report.

Ann Hematol. 2014 Mar;93(3):529-30. doi: 10.1007/s00277-013-1835-9. Epub 2013 Jul 3.

Clinical assessment of bortezomib for multiple myeloma in comparison with thalidomide.

J Pharm Pharm Sci. 2011;14(1):78-89.

Clinical management of myeloma--state of the art.

Cancer Treat Rev. 2010 May;36 Suppl 2:S1-2. doi: 10.1016/S0305-7372(10)00081-2.

New agents and approaches in the treatment of multiple myeloma.

Clin Adv Hematol Oncol. 2003 Mar;1(3):151-2.